English

Interim report January – March 2020: Good growth but uncertain second quarter

Report this content

First quarter

  • Sales amounted to SEK 334 (312) million, corresponding to an increase of 7 percent in SEK. Sales increased by 5 percent in local currency and consisted of organic growth.
  • Operating income before depreciation and amortisation (EBITDA) amounted to SEK 116 (126) million, corresponding to a margin of 35 (40) percent. Fluctuations in exchange rates positively impacted EBITDA by SEK 10 million.
  • Net income amounted to SEK 80 (86) million, which gave earnings per share of SEK 0.74 (0.79).

After the end of the period

  • Large reduction in inflow of orders due to covid-19 during the beginning of the second quarter. Sales during the first weeks of April amounted to approximately a third of those in the corresponding period the previous year. In the company’s assessment, the second quarter will be very weak.
  • Due to the great uncertainty prevailing from the extensive spread of covid-19, Vitrolife’s Board decided to postpone the Annual General Meeting to a later date. The Annual General Meeting will be held in accordance with current legislation.

Gothenburg, April 23, 2020
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 am CET on April 23, 2020.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Subscribe

Documents & Links